Current portfolio

XyloCor Therapeutics

US biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease

  • Sector
    Healthcare
  • Country
    United States
  • Fund
    LSP 6
  • Entry
    2018
  • Web
Logo

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo
A purpose-driven global investment organization
© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180